Get started
Knight Therapeutics, Inc.Knight Therapeutics, Inc.Knight Therapeutics, Inc.

Knight Therapeutics, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasDiscussionsTechnicalsForecastSeasonals

GUD chart


Full chart

GUD upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪620.85 M‬ CAD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
1,878.79
Basic EPS (TTM)
0.00 CAD
Net income (FY)
‪4.33 M‬ CAD
Revenue (FY)
‪371.30 M‬ CAD
Shares float
‪69.37 M‬
Beta (1Y)
0.33

Employees


Employees (FY)
745
Change (1Y)
+20 +2.76%
Revenue / Employee (1Y)
‪498.39 K‬ CAD
Net income / Employee (1Y)
‪5.81 K‬ CAD

About Knight Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Samira Sakhia
Website
gud-knight.com
Headquarters
Montréal
Founded
2013
ISIN
CA4990531069
FIGI
BBG006373G71
Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The firm also focuses on building a portfolio of innovative products through in-licensing or acquiring product rights. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montréal, Canada.

Check out other big names from the same industry as GUD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

GUD news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of GUD is 6.16 CAD — it has increased by 0.48% in the past 24 hours. Watch Knight Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSX exchange Knight Therapeutics, Inc. stocks are traded under the ticker GUD.
GUD stock has fallen by −2.81% compared to the previous week, the month change is a −2.66% fall, over the last year Knight Therapeutics, Inc. has showed a 1.32% increase.
We've gathered analysts' opinions on Knight Therapeutics, Inc. future price: according to them, GUD price has a max estimate of 10.00 CAD and a min estimate of 6.15 CAD. Watch GUD chart and read a more detailed Knight Therapeutics, Inc. stock forecast: see what analysts think of Knight Therapeutics, Inc. and suggest that you do with its stocks.
GUD reached its all-time high on Dec 5, 2016 with the price of 11.03 CAD, and its all-time low was 3.51 CAD and was reached on Mar 3, 2014. View more price dynamics on GUD chart.
See other stocks reaching their highest and lowest prices.
GUD stock is 1.63% volatile and has beta coefficient of 0.33. Track Knight Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Knight Therapeutics, Inc. there?
Today Knight Therapeutics, Inc. has the market capitalization of ‪620.85 M‬, it has decreased by −3.11% over the last week.
Yes, you can track Knight Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Knight Therapeutics, Inc. is going to release the next earnings report on Nov 6, 2025. Keep track of upcoming events with our Earnings Calendar.
GUD earnings for the last quarter are −0.13 CAD per share, whereas the estimation was 0.02 CAD resulting in a −798.29% surprise. The estimated earnings for the next quarter are −0.01 CAD per share. See more details about Knight Therapeutics, Inc. earnings.
Knight Therapeutics, Inc. revenue for the last quarter amounts to ‪108.54 M‬ CAD, despite the estimated figure of ‪95.22 M‬ CAD. In the next quarter, revenue is expected to reach ‪107.27 M‬ CAD.
GUD net income for the last quarter is ‪−12.62 M‬ CAD, while the quarter before that showed ‪2.19 M‬ CAD of net income which accounts for −677.67% change. Track more Knight Therapeutics, Inc. financial stats to get the full picture.
No, GUD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 22, 2025, the company has 745 employees. See our rating of the largest employees — is Knight Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Knight Therapeutics, Inc. EBITDA is ‪42.12 M‬ CAD, and current EBITDA margin is 16.33%. See more stats in Knight Therapeutics, Inc. financial statements.
Like other stocks, GUD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Knight Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Knight Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Knight Therapeutics, Inc. stock shows the buy signal. See more of Knight Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.